Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
4.05% $3.35
America/New_York / 28 mar 2024 @ 13:57
FUNDAMENTALS | |
---|---|
MarketCap: | 99.63 mill |
EPS: | -2.80 |
P/E: | -1.200 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 29.74 mill |
Avg Daily Volume: | 0.414 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.200 | sector: PE 15.43 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -1.200 | industry: PE 40.47 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.771 (-47.14%) $-1.579 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.56 - 4.08 ( +/- 22.80%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Day Lucy | Buy | 55 000 | Stock Option (right to buy) |
2024-03-15 | Day Lucy | Buy | 27 500 | Common Stock |
2024-03-15 | Eizen Joshua M | Buy | 60 000 | Stock Option (right to buy) |
2024-03-15 | Eizen Joshua M | Buy | 30 000 | Common Stock |
2024-03-15 | Krause Kevin Michael | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
65.21 |
Last 100 transactions |
Buy: 3 419 514 | Sell: 646 406 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.35 (4.05% ) |
Volume | 0.103 mill |
Avg. Vol. | 0.414 mill |
% of Avg. Vol | 24.89 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $20.00 | N/A | Active |
---|
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.